Scholarlink

<p>Precision oncology, a transformative paradigm in cancer therapeutics, leverages molecular profiling to design personalized interventions. Building on our prior discovery of ISG15’s role in pancreatic cancer stem cell (CSC) generation, we identified co-upregulation of ISG15 and HMGCR in pancreatic ductal adenocarcinoma (PDAC). Dual suppression of ISG15 and HMGCR triggered synthetic lethality, effectively eradicating CSCs and impairing tumor progression. To exploit this synergy, we engineered a hyaluronic acid-coated liposomal nanoplatform (LNP-Kd/Statin) for co-delivery of ISG15-targeting siRNA and HMGCR-inhibiting statins. Mechanistically, ISG15 directly interacts with HMGCR, and the knockdown of ISG15 stabilizes the HMGCR protein by inhibiting K48 ubiquitin-proteasomal degradation, a process that occurs independently of ISGylation, paradoxically elevating cholesterol levels to sustain cell survival while depleting metabolic intermediates, thereby inducing vulnerability. Sterolomics profiling confirmed this metabolic rewiring, linking cholesterol flux collapse to CSC elimination. Our findings not only elucidate a novel ISG15-HMGCR regulatory axis in PDAC pathogenesis but also establish a nanotechnology-enabled strategy to disrupt cancer stemness through metabolic targeting. This work advances the translational potential of synthetic lethality in precision oncology for aggressive malignancies.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • Jia Sun,
  • Jia-Mei Wang,
  • Qi Zhang,
  • Wen-Ying Lin,
  • Lin Tang,
  • Shi-Yang Lu,
  • Bai-Qiang Li,
  • Zhen-Xian Du,
  • Hua-Qin Wang

摘要

Precision oncology, a transformative paradigm in cancer therapeutics, leverages molecular profiling to design personalized interventions. Building on our prior discovery of ISG15’s role in pancreatic cancer stem cell (CSC) generation, we identified co-upregulation of ISG15 and HMGCR in pancreatic ductal adenocarcinoma (PDAC). Dual suppression of ISG15 and HMGCR triggered synthetic lethality, effectively eradicating CSCs and impairing tumor progression. To exploit this synergy, we engineered a hyaluronic acid-coated liposomal nanoplatform (LNP-Kd/Statin) for co-delivery of ISG15-targeting siRNA and HMGCR-inhibiting statins. Mechanistically, ISG15 directly interacts with HMGCR, and the knockdown of ISG15 stabilizes the HMGCR protein by inhibiting K48 ubiquitin-proteasomal degradation, a process that occurs independently of ISGylation, paradoxically elevating cholesterol levels to sustain cell survival while depleting metabolic intermediates, thereby inducing vulnerability. Sterolomics profiling confirmed this metabolic rewiring, linking cholesterol flux collapse to CSC elimination. Our findings not only elucidate a novel ISG15-HMGCR regulatory axis in PDAC pathogenesis but also establish a nanotechnology-enabled strategy to disrupt cancer stemness through metabolic targeting. This work advances the translational potential of synthetic lethality in precision oncology for aggressive malignancies.

Graphical Abstract